Tony Chen

Tony Chen helps life science companies protect their products under China’s nascent pharmaceutical patent linkage system, and assists them with procuring patents, negotiating license agreements, and enforcing intellectual property rights in Chinese courts. He advises life science venture capital investors on mitigating IP risks associated with investing in Chinese biotechnology companies. He also acts for Chinese biotechnology clients in licensing technology and creating IP assets on a worldwide basis. Tony is Chairman of the Bayhelix Group, a network of senior executives in the cross-border China life science industry. Tony promotes the enhancement of pharmaceutical IP protection in China in his position as an advisory member of the U.S.-China IP Cooperation Dialogue organized by the U.S. Chamber of Commerce and Renmin University of China.